---
title: "Northeast Pharmaceutical Group Co.,Ltd. (000597.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/000597.SZ.md"
symbol: "000597.SZ"
name: "Northeast Pharmaceutical Group Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-21T16:51:51.828Z"
locales:
  - [en](https://longbridge.com/en/quote/000597.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/000597.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/000597.SZ.md)
---

# Northeast Pharmaceutical Group Co.,Ltd. (000597.SZ)

## Company Overview

Northeast Pharmaceutical Group Co., Ltd. engages in chemical pharmaceuticals manufacturing, pharmaceutical distribution, pharmaceutical engineering, biopharmaceuticals, and other businesses in China. It offers vitamin products, such as vitamin C, vitamin B1, vitamin B6, and L-carnitine series; anti- infective products, such as fosfomycin series, azithromycin series, amantadine series, polyalkali hydrochloride, chloramphenicol, and other products; and reproductive system and hormone products comprising carboprost suppositories, carboprost tromethamine, dapoxetine hydrochloride, and levonorgestrel and tadalafil tablets. It also provides nervous system products, such as piracetam series, levetiracetam series, vinpocetine, and other products; narcotics and psychotropic drugs and related products, including morphine hydrochloride injections and tablets, oxycodone hydrochloride injection, compound glycyrrhiza series, and acetaminophen-codeine tablets; anti-AIDS products comprising Krughar /zidovudine tablets and capsules, efavirenz tablets, and other products; and in vitro biological diagnostic reagent products for HIV, HBV, HCV, HPV, and TB.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.nepharm.com.cn](https://www.nepharm.com.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:13.000Z

**Overall: C (0.53)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 118 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -5.00% |  |
| Net Profit YoY | -35.56% |  |
| P/B Ratio | 1.24 |  |
| Dividend Ratio | 2.07% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 6893828982.31 |  |
| Revenue | 7120059984.64 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 4.59% | C |
| Profit Margin | 3.51% | C |
| Gross Margin | 28.44% | C |
| Revenue YoY | -5.00% | D |
| Net Profit YoY | -35.56% | D |
| Total Assets YoY | -0.16% | D |
| Net Assets YoY | 1.43% | C |
| Cash Flow Margin | 460.95% | A |
| OCF YoY | -5.00% | D |
| Turnover | 0.52 | C |
| Gearing Ratio | 58.17% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Northeast Pharmaceutical Group Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-5.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-35.56%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.24",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "2.07%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "6893828982.31",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "7120059984.64",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "4.59%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "3.51%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "28.44%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "-5.00%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-35.56%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-0.16%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "1.43%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "460.95%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "-5.00%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.52",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "58.17%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 27.64 | 69/215 | 21.94 | 20.50 | 19.83 |
| PB | 1.25 | 26/215 | 1.51 | 1.43 | 1.38 |
| PS (TTM) | 0.97 | 8/215 | 1.13 | 1.10 | 1.02 |
| Dividend Yield | 2.06% | 64/215 | 1.92% | 1.87% | 1.77% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/000597.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/000597.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/000597.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/000597.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**